Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to $13.9 million.

  • Standard Biotools' Receivables - Net fell 6057.11% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year decrease of 6057.11%. This contributed to the annual value of $15.0 million for FY2024, which is 2488.98% down from last year.
  • As of Q3 2025, Standard Biotools' Receivables - Net stood at $13.9 million, which was down 6057.11% from $15.0 million recorded in Q2 2025.
  • In the past 5 years, Standard Biotools' Receivables - Net ranged from a high of $36.0 million in Q1 2024 and a low of $10.9 million during Q2 2022
  • Its 5-year average for Receivables - Net is $19.7 million, with a median of $15.7 million in 2021.
  • Per our database at Business Quant, Standard Biotools' Receivables - Net skyrocketed by 14829.01% in 2024 and then crashed by 6057.11% in 2025.
  • Quarter analysis of 5 years shows Standard Biotools' Receivables - Net stood at $18.3 million in 2021, then fell by 5.68% to $17.3 million in 2022, then grew by 15.58% to $20.0 million in 2023, then decreased by 24.89% to $15.0 million in 2024, then dropped by 7.12% to $13.9 million in 2025.
  • Its Receivables - Net stands at $13.9 million for Q3 2025, versus $15.0 million for Q2 2025 and $35.5 million for Q1 2025.